CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
We are very excited to launch our new website! Please take a few moments to click around and explore...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...